SAN FRANCISCO – News of the tentative April 1 advisory committee to discuss Mannkind Corp.’s resubmitted new drug application for inhaled insulin Afrezza (insulin human [rDNA origin]) powder sent the Valencia, Calif.-based firm’s shares falling 16 percent last week.